Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm
ER Gerstner, RL Fine - Journal of clinical oncology, 2007 - ascopubs.org
There is no accepted standard of care for the chemotherapy treatment of metastatic brain
tumors, which has been generally limited to lipophilic alkylators, which may not have efficacy …
tumors, which has been generally limited to lipophilic alkylators, which may not have efficacy …
The role of chemotherapy in brain metastases
MJ Van den Bent - European Journal of Cancer, 2003 - Elsevier
Despite the widely held belief of the resistance to chemotherapy of brain metastases, central
nervous sytem metastases of a malignancy are equally sensitive to chemotherapy as its …
nervous sytem metastases of a malignancy are equally sensitive to chemotherapy as its …
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
R Rangwala, R Leone, YC Chang, LA Fecher… - Autophagy, 2014 - Taylor & Francis
Blocking autophagy with hydroxychloroquine (HCQ) augments cell death associated with
alkylating chemotherapy in preclinical models. This phase I study evaluated the maximum …
alkylating chemotherapy in preclinical models. This phase I study evaluated the maximum …
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas
MF Paz, R Yaya-Tur, I Rojas-Marcos, G Reynes… - Clinical Cancer …, 2004 - AACR
Purpose: The DNA repair enzyme O 6-methylguanine DNA methyltransferase (MGMT)
inhibits the killing of tumor cells by alkylating agents, and its loss in cancer cells is …
inhibits the killing of tumor cells by alkylating agents, and its loss in cancer cells is …
Temozolomide: a milestone in neuro-oncology and beyond?
N Mutter, R Stupp - Expert review of anticancer therapy, 2006 - Taylor & Francis
Temozolomide (Temodal®, Temodar), an imidazol derivative, is a second-generation
alkylating agent. The orally available prodrug with the capacity of crossing the blood–brain …
alkylating agent. The orally available prodrug with the capacity of crossing the blood–brain …
[HTML][HTML] Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy …
GA Pesce, D Klingbiel, K Ribi, A Zouhair… - European Journal of …, 2012 - Elsevier
PURPOSE: Patients with brain metastases (BM) rarely survive longer than 6months and are
commonly excluded from clinical trials. We explored two combined modality regimens with …
commonly excluded from clinical trials. We explored two combined modality regimens with …
Temozolomide and unusual indications: review of literature
Z Tatar, E Thivat, E Planchat, P Gimbergues… - Cancer treatment …, 2013 - Elsevier
Temozolomide (TMZ) was first known to be useful as a radiosensitiser in both primary brain
tumours like glioblastoma multiforme and oligodendroglioma. Later, TMZ proved its efficacy …
tumours like glioblastoma multiforme and oligodendroglioma. Later, TMZ proved its efficacy …
Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study
CG Giorgio, D Giuffrida, A Pappalardo, A Russo… - Lung cancer, 2005 - Elsevier
INTRODUCTION:: The primary tumour type most likely to metastasize to the brain is lung
cancer. In heavily pre-treated patients, limited therapeutic option is available and the results …
cancer. In heavily pre-treated patients, limited therapeutic option is available and the results …
Baseline neutrophil–lymphocyte ratio is associated with baseline and subsequent presence of brain metastases in advanced non-small-cell lung cancer
YW Koh, JH Choi, MS Ahn, YW Choi, HW Lee - Scientific reports, 2016 - nature.com
We examined the predictive value of neutrophil–lymphocyte ratio (NLR) by examining their
association with the baseline presence and subsequent development of brain metastases in …
association with the baseline presence and subsequent development of brain metastases in …
Docking and dynamic simulation study of Crizotinib and Temozolomide drug with Glioblastoma and NSCLC target to identify better efficacy of the drug
Abstract Background Crizotinib and Temozolomide are the two major chemotherapy drugs
used for the treatment of cancers. Crizotinib is used as a target chemotherapy drug in many …
used for the treatment of cancers. Crizotinib is used as a target chemotherapy drug in many …